Safety profile of colocasia esculenta tuber extracts in benign prostate hyperplasia.

Introduction: This study was motivated by the increasing global incidence of benign prostatic hyperplasia (BPH) and the promising potential of nutraceuticals as complementary therapies in ameliorating its burden. We report the safety profile of C. esculenta tuber extracts, a novel nutraceutical in benign prostate hyperplasia in a rat model.

In-vivo and in-silico studies revealed the molecular mechanisms of phenolics as novel chemotherapy against benign prostatic hyperplasia via inhibition of 5α-reductase and α1-adrenoceptor.

Benign Prostatic Hyperplasia (BPH) is a major cause of lower urinary tract infections and erectile dysfunction thus a major contributor to lowering the quality of life among older men. In this study, we investigated the molecular mechanism of CE as a novel agent for BPH chemotherapy. In vivo we assigned 45 male Wistar albino rats about 6 weeks old into 9 experimental groups (n = 5).